{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:27:38Z","timestamp":1791908858239,"version":"4.3.4"},"reference-count":69,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.vaccine.2013.03.021","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T09:31:58Z","timestamp":1363858318000},"page":"4247-4251","source":"Crossref","is-referenced-by-count":87,"title":["Recombinant MVA vaccines: dispelling the myths"],"prefix":"10.1016","volume":"31","author":[{"given":"Matthew G.","family":"Cottingham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles W.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"December (23)","key":"10.1016\/j.vaccine.2013.03.021_bib0005","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1073\/pnas.80.23.7155","article-title":"Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters","volume":"80","author":"Smith","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"April (5908)","key":"10.1016\/j.vaccine.2013.03.021_bib0010","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/302490a0","article-title":"Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen","volume":"302","author":"Smith","year":"1983","journal-title":"Nature"},{"issue":"September (17)","key":"10.1016\/j.vaccine.2013.03.021_bib0015","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1073\/pnas.80.17.5364","article-title":"Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin","volume":"80","author":"Panicali","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2013.03.021_bib0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-1-4899-1382-1_2","article-title":"Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates","volume":"397","author":"Moss","year":"1996","journal-title":"Adv Exp Med Biol"},{"issue":"September (3)","key":"10.1016\/j.vaccine.2013.03.021_bib0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568005033481123","article-title":"Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery","volume":"3","author":"Sutter","year":"2003","journal-title":"Current drug targets Infectious disorders"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2013.03.021_bib0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/14760584.4.1.63","article-title":"Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry","volume":"4","author":"Skinner","year":"2005","journal-title":"Expert Rev Vaccines"},{"issue":"February (5)","key":"10.1016\/j.vaccine.2013.03.021_bib0035","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2013.03.021_bib0040","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/erv.10.104","article-title":"Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV","volume":"9","author":"Vaccari","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2013.03.021_bib0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/156652311795684731","article-title":"NYVAC as vaccines against emergent infectious diseases and cancer","volume":"11","author":"Gomez","year":"2011","journal-title":"Curr Gene Ther"},{"issue":"July (30)","key":"10.1016\/j.vaccine.2013.03.021_bib0050","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1016\/j.vaccine.2006.11.066","article-title":"Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform","volume":"25","author":"Poulet","year":"2007","journal-title":"Vaccine"},{"issue":"November (51)","key":"10.1016\/j.vaccine.2013.03.021_bib0055","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1016\/j.vaccine.2009.09.033","article-title":"Poxvirus-vectored vaccines for rabies--a review","volume":"27","author":"Weyer","year":"2009","journal-title":"Vaccine"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2013.03.021_bib0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr Opin Immunol"},{"issue":"December (5\u20136)","key":"10.1016\/j.vaccine.2013.03.021_bib0065","first-page":"375","article-title":"[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl Bakteriol [B]"},{"issue":"November (2)","key":"10.1016\/j.vaccine.2013.03.021_bib0070","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/viro.1998.9397","article-title":"Marker rescue of the host range restriction defects of modified vaccinia virus Ankara","volume":"251","author":"Wyatt","year":"1998","journal-title":"Virology"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2013.03.021_bib0075","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1099\/vir.0.83156-0","article-title":"Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara","volume":"88","author":"Meisinger-Henschel","year":"2007","journal-title":"J Gen Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2013.03.021_bib0080","doi-asserted-by":"crossref","first-page":"e5934","DOI":"10.1371\/journal.pone.0005934","article-title":"Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A","volume":"4","author":"Whelan","year":"2009","journal-title":"PLoS ONE"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2013.03.021_bib0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/eji.200939754","article-title":"Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells","volume":"40","author":"Scriba","year":"2010","journal-title":"Eur J Immunol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2013.03.021_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"January (115)","key":"10.1016\/j.vaccine.2013.03.021_bib0095","doi-asserted-by":"crossref","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci Transl Med"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2013.03.021_bib0100","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"O\u2018Hara","year":"2012","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2013.03.021_bib0105","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PLoS ONE"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2013.03.021_bib0110","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","volume":"19","author":"Sheehy","year":"2011","journal-title":"Mol Ther"},{"issue":"January (115)","key":"10.1016\/j.vaccine.2013.03.021_bib0115","first-page":"ra1","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"issue":"November (9653)","key":"10.1016\/j.vaccine.2013.03.021_bib0120","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"issue":"November (9653)","key":"10.1016\/j.vaccine.2013.03.021_bib0125","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2013.03.021_bib0130","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.4049\/jimmunol.1102756","article-title":"The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope","volume":"188","author":"de Souza","year":"2012","journal-title":"J Immunol"},{"issue":"May (21)","key":"10.1016\/j.vaccine.2013.03.021_bib0135","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1016\/j.vaccine.2005.08.048","article-title":"Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis","volume":"24","author":"Gilbert","year":"2006","journal-title":"Vaccine"},{"issue":"March (13)","key":"10.1016\/j.vaccine.2013.03.021_bib0140","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1073\/pnas.0406381102","article-title":"Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara","volume":"102","author":"Webster","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2013.03.021_bib0145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2567.2011.03517.x","article-title":"T-cell-inducing vaccines \u2013 what's the future","volume":"135","author":"Gilbert","year":"2012","journal-title":"Immunology"},{"issue":"November (20)","key":"10.1016\/j.vaccine.2013.03.021_bib0150","first-page":"1863","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"Agnandji","year":"2011","journal-title":"N Engl J Med"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2013.03.021_bib0155","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"May (2)","key":"10.1016\/j.vaccine.2013.03.021_bib0160","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"issue":"December (52)","key":"10.1016\/j.vaccine.2013.03.021_bib0165","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1016\/j.vaccine.2009.05.095","article-title":"Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain","volume":"27","author":"Suter","year":"2009","journal-title":"Vaccine"},{"issue":"September (1\/2)","key":"10.1016\/j.vaccine.2013.03.021_bib0170","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jviromet.2010.04.012","article-title":"Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome","volume":"168","author":"Cottingham","year":"2010","journal-title":"J Virol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2013.03.021_bib0175","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01641272","article-title":"Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA","volume":"3","author":"Mayr","year":"1975","journal-title":"Infection"},{"issue":"December (24)","key":"10.1016\/j.vaccine.2013.03.021_bib0180","doi-asserted-by":"crossref","first-page":"13049","DOI":"10.1128\/JVI.05779-11","article-title":"Genomic analysis of the vaccinia virus strain variants found in Dryvax vaccine","volume":"85","author":"Qin","year":"2011","journal-title":"J Virol"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2013.03.021_bib0185","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/aid.2007.0205","article-title":"Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C","volume":"24","author":"Burgers","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"March (2)","key":"10.1016\/j.vaccine.2013.03.021_bib0190","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2007.10.033","article-title":"Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA","volume":"372","author":"Wyatt","year":"2008","journal-title":"Virology"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2013.03.021_bib0195","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/bit.24342","article-title":"Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors","volume":"109","author":"Cottingham","year":"2012","journal-title":"Biotechnol Bioeng"},{"issue":"July (14)","key":"10.1016\/j.vaccine.2013.03.021_bib0200","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1128\/JVI.00687-09","article-title":"Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection","volume":"83","author":"Wyatt","year":"2009","journal-title":"J Virol"},{"issue":"May (21)","key":"10.1016\/j.vaccine.2013.03.021_bib0205","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1016\/j.vaccine.2005.08.037","article-title":"Genetic stability of recombinant MVA-BN","volume":"24","author":"Timm","year":"2006","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2013.03.021_bib0210","doi-asserted-by":"crossref","first-page":"e40167","DOI":"10.1371\/journal.pone.0040167","article-title":"Cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA","volume":"7","author":"Orubu","year":"2012","journal-title":"PLoS One"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2013.03.021_bib0215","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1128\/JVI.64.5.2448-2451.1990","article-title":"Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus","volume":"64","author":"Earl","year":"1990","journal-title":"J Virol"},{"issue":"January (4)","key":"10.1016\/j.vaccine.2013.03.021_bib0220","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.vaccine.2007.11.036","article-title":"Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines","volume":"26","author":"Wyatt","year":"2008","journal-title":"Vaccine"},{"issue":"October (15)","key":"10.1016\/j.vaccine.2013.03.021_bib0225","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0264-410X(96)00072-2","article-title":"Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model","volume":"14","author":"Wyatt","year":"1996","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2013.03.021_bib0230","doi-asserted-by":"crossref","first-page":"e20067","DOI":"10.1371\/journal.pone.0020067","article-title":"Dual neonate vaccine platform against HIV-1 and M. tuberculosis","volume":"6","author":"Hopkins","year":"2011","journal-title":"PLoS One"},{"issue":"September (17)","key":"10.1016\/j.vaccine.2013.03.021_bib0235","doi-asserted-by":"crossref","first-page":"8743","DOI":"10.1128\/JVI.00604-10","article-title":"Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses","volume":"84","author":"Baur","year":"2010","journal-title":"J Virol"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2013.03.021_bib0240","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/infdis\/jiq105","article-title":"Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles","volume":"203","author":"Goepfert","year":"2011","journal-title":"J Infect Dis"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2013.03.021_bib0245","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1099\/vir.0.024885-0","article-title":"Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A\/H1N1 vaccine in the ferret model","volume":"91","author":"Kreijtz","year":"2010","journal-title":"J Gen Virol"},{"issue":"November (22)","key":"10.1016\/j.vaccine.2013.03.021_bib0250","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-10-2082","article-title":"Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study","volume":"16","author":"Amato","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"January (5)","key":"10.1016\/j.vaccine.2013.03.021_bib0255","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.vaccine.2008.11.066","article-title":"An avian cell line designed for production of highly attenuated viruses","volume":"27","author":"Jordan","year":"2009","journal-title":"Vaccine"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2013.03.021_bib0260","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.biologicals.2010.11.005","article-title":"A chemically defined production process for highly attenuated poxviruses","volume":"39","author":"Jordan","year":"2011","journal-title":"Biologicals"},{"issue":"November (Suppl 8)","key":"10.1016\/j.vaccine.2013.03.021_bib0265","doi-asserted-by":"crossref","first-page":"O1","DOI":"10.1186\/1753-6561-5-S8-O1","article-title":"Highly efficient, chemically defined and fully scalable biphasic production of vaccine viruses","volume":"5","author":"Jordan","year":"2011","journal-title":"BMC proceedings"},{"issue":"September\u2013October (5)","key":"10.1016\/j.vaccine.2013.03.021_bib0270","first-page":"419","article-title":"The avian EB66(R) cell line, application to vaccines, and therapeutic protein production","volume":"64","author":"Brown","year":"2010","journal-title":"PDA J Pharm Sci Technol"},{"issue":"Nov 22 (Suppl 8)","key":"10.1016\/j.vaccine.2013.03.021_bib0275","doi-asserted-by":"crossref","first-page":"P52","DOI":"10.1186\/1753-6561-5-S8-P52","article-title":"Avian cell line \u2013 Technology for large scale vaccine production","volume":"5","author":"Kraus","year":"2011","journal-title":"BMC proceedings"},{"issue":"2","key":"10.1016\/j.vaccine.2013.03.021_bib0280","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/bit.22797","article-title":"Purification of cell culture-derived modified vaccinia ankara virus by pseudo-affinity membrane adsorbers and hydrophobic interaction chromatography","volume":"107","author":"Wolff","year":"2010","journal-title":"Biotechnol Bioeng"},{"issue":"March (4)","key":"10.1016\/j.vaccine.2013.03.021_bib0285","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/bit.22595","article-title":"Capturing of cell culture-derived modified Vaccinia Ankara virus by ion exchange and pseudo-affinity membrane adsorbers","volume":"105","author":"Wolff","year":"2010","journal-title":"Biotechnol Bioeng"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2013.03.021_bib0290","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1099\/vir.0.19568-0","article-title":"Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses","volume":"85","author":"Laidlaw","year":"2004","journal-title":"J Gen Virol"},{"issue":"May (22)","key":"10.1016\/j.vaccine.2013.03.021_bib0295","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.vaccine.2006.03.029","article-title":"Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area","volume":"24","author":"Bejon","year":"2006","journal-title":"Vaccine"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2013.03.021_bib0300","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-05-2732","article-title":"Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I\/II trial","volume":"12","author":"Harrop","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"October (8)","key":"10.1016\/j.vaccine.2013.03.021_bib0305","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.addr.2006.05.005","article-title":"Recombinant viral vectors: cancer vaccines","volume":"58","author":"Harrop","year":"2006","journal-title":"Advanced drug delivery reviews"},{"issue":"November\u2013December (9)","key":"10.1016\/j.vaccine.2013.03.021_bib0310","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/CJI.0b013e3181f5dac7","article-title":"Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients","volume":"33","author":"Harrop","year":"2010","journal-title":"J Immunother"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2013.03.021_bib0315","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1086\/421118","article-title":"Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men","volume":"189","author":"Moorthy","year":"2004","journal-title":"J Infect Dis"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2013.03.021_bib0320","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/421266","article-title":"Modified vaccinia Ankara: potential as an alternative smallpox vaccine","volume":"38","author":"McCurdy","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2013.03.021_bib0325","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/v4050889","article-title":"Authentication of the R06E fruit bat cell line","volume":"4","author":"Jordan","year":"2012","journal-title":"Viruses"},{"issue":"October (1)","key":"10.1016\/j.vaccine.2013.03.021_bib0330","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.virusres.2009.06.007","article-title":"Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara","volume":"145","author":"Jordan","year":"2009","journal-title":"Virus Res"},{"issue":"November (2)","key":"10.1016\/j.vaccine.2013.03.021_bib0335","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.1997.8845","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line","volume":"238","author":"Carroll","year":"1997","journal-title":"Virology"},{"issue":"February (79)","key":"10.1016\/j.vaccine.2013.03.021_bib0340","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells","author":"Drexler","year":"1998","journal-title":"J Gen Virol"},{"issue":"May (79)","key":"10.1016\/j.vaccine.2013.03.021_bib0345","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","author":"Blanchard","year":"1998","journal-title":"J Gen Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13003058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13003058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T19:40:55Z","timestamp":1715110855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13003058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":69,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0264410X13003058"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.03.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}